Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04405271
Other study ID # 5616
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date July 31, 2020
Est. completion date November 15, 2020

Study information

Verified date July 2020
Source Hospital Italiano de Buenos Aires
Contact Waldo H Belloso, MD
Phone +541149590200
Email waldo.belloso@hiba.org.ar
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A randomized parallel double-blinded placebo-controlled clinical trial to evaluate the effect of Emtricitabine/Tenofovir alafenamide (FTC/TAF) compared with placebo on the risk of developing SARS-CoV-2 disease (COVID-19) in healthcare workers with high transmission risk in addition to currently recommended control measures.


Description:

Randomized, double-blind, placebo-controlled clinical trial. Phase III clinical trial for a new indication

Rationale One of the most affected subgroups during the current pandemic is represented by healthcare workers. In Argentina between 14 and 17% of the total COVID-19 cases are represented by this subgroup. In this sense, it appears as an adequate strategy testing the efficacy of pharmacological PrEP approaches on top of the currently recommended control measures.

The use of placebo is warranted for two main reasons: all healthcare workers will be allowed and encouraged to comply with non-pharmacological infection control measures for the protection of viral transmission. On the other hand, the use of a blinded placebo is intended for avoiding relaxation of the non-pharmacological control measures.

Tenofovir has been identified by both docking and in vitro studies as an inhibitor of RdRp (RNA dependent RNA polymerase) of coronavirus.

FTC/TAF has the additional advantage that is already being used in a pre-exposure prophylaxis setting and its safety is widely known.

Main objective To evaluate the risk of developing SARS-CoV-2 disease (COVID-19) in healthcare workers with high transmission risk in addition to currently recommended control measures.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 1378
Est. completion date November 15, 2020
Est. primary completion date November 15, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Healthcare workers voluntarily deciding to participate in the study

2. Understanding the study purpose

3. Having between 18 and 70 years old

4. Having a high transmission risk for Covid-19. Physicians, nurses, lab technicians, physical therapists, or cleaning personnel working at COVID-19 areas, hospital emergency areas, or Intensive care units from healthcare institutions with the direct assistance of patients with Covid-19.

5. Not having a prior diagnosis of SARS-CoV-2 infection (COVID-19)

6. Having a negative IgM/IgG antibodies test for SARS-CoV-2 (COVID-19) prior to study entry

7. Negative pregnancy test for childbearing age women within 7 days prior to study entry.

8. Childbearing age males and females should comply with the use of a proven contraceptive method (double barrier methods, oral contraceptives or contraceptive hormone implants) during the course of the study and at least one month after study completion.

Exclusion Criteria:

1. Having symptoms compatible with COVID-19

2. Diagnosed HIV infection

3. Current use of Pre-exposure prophylaxis for HIV

4. Diagnosed Hepatitis B infection.

5. Diagnosed renal insufficiency and or current hemodialysis need

6. Diagnosed osteoporosis under pharmacological treatment.

7. Weight < 40kg

8. Current immunosuppressive or serious hematological condition

9. Prior use of pre-exposure prophylaxis for SARS-CoV-2

10. Current pregnancy or pregnancy plan within the study course.

11. Current breastfeeding

12. Known hypersensitivity to any of the study medication components.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet
Emtricitabine/Tenofovir alafenamide (FTC/TAF) in 200 mg/25 mg tablets. A dose of 1 tablet per day will be administered for a total of 12 weeks
Placebo
A dose of 1 tablet per day will be administered for a total of 12 weeks.

Locations

Country Name City State
Argentina Sociedad Argentina de Infectología, A. J. Carranza 974 Ciudad Autonoma de Buenos Aires Capital Federal

Sponsors (2)

Lead Sponsor Collaborator
Hospital Italiano de Buenos Aires Sociedad Argentina de Infectología (SADI) (Argentine Society of Infectious Diseases)

Country where clinical trial is conducted

Argentina, 

References & Publications (2)

Castillo-Mancilla JR, Meditz A, Wilson C, Zheng JH, Palmer BE, Lee EJ, Gardner EM, Seifert S, Kerr B, Bushman LR, MaWhinney S, Anderson PL. Reduced immune activation during tenofovir-emtricitabine therapy in HIV-negative individuals. J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):495-501. doi: 10.1097/QAI.0000000000000529. — View Citation

Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci. 2020 May 1;248:117477. doi: 10.1016/j.lfs.2020.117477. Epub 2020 Feb 28. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary COVID-19 incident cases SARS-CoV-2 disease (COVID-19) with or without symptoms at week 12 of treatment as defined by the presence of specific antibodies against the virus. Positive cases will be confirmed by PCR During treatment (12 weeks)
Secondary Number of asymptomatic SARS-CoV-2 (Covid-19) infections confirmed by serology Number of asymptomatic SARS-CoV-2 (Covid-19) infections confirmed by serology During treatment (12 weeks)
Secondary Severity of symptomatic COVID-19 Severity of symptomatic SARS-CoV-2 (Covid-19) infections as defined by the following categories:
Mild symptoms: malaise, fever, cough, arthralgia myalgias,
Moderate symptoms: same as above plus shortness of breath
Severe symptoms: clinical status requiring admission in Intensive care unit
During treatment (12 weeks)
Secondary Respiratory symptom duration in days Respiratory symptom duration in days During treatment (12 weeks)
Secondary Relation between treatments and symptoms duration Relation between treatments and symptoms duration During treatment (12 weeks)
Secondary Time course of specific IgM/IgG seroconversion Time course of specific IgM/IgG seroconversion During treatment (12 weeks)
See also
  Status Clinical Trial Phase
Withdrawn NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure